

27 October 2023

Completion of Consolidation of Capital

Perth, Australia, and Minneapolis, USA: TrivarX Limited ('the **Company'**) (ASX: TRI) (OTCPINK: MDBIF) is pleased to advise that the consolidation of capital approved by shareholders at the Company's general meeting on 6 October 2023, has been completed.

The Company's post consolidation capital structure is as follows:

Quoted Securities	ASX Code	Number
Ordinary fully paid shares	TRI	335,719,543
Options expiring 28 February 2024 exercisable at \$0.30 each	TRIOC	26,279,275

Unquoted Securities	ASX Code	Number
Options Expiring Various Dates and Various Exercise Prices	TRIAD	53,893,100
Options expiring 8 December 2025 exercisable at \$0.22 each	TRIAO	562,500
Options expiring 15 June 2025 exercisable at \$0.08 each	TRIAR	90,099,051

New holding statements will be despatched to security holders advising them of their securities held on a post-consolidation basis. Where the consolidation has resulted in a fraction of a security held, that fraction has been rounded up to the nearest whole security.

This announcement is authorised for release by the Board of Directors of TrivarX Limited.

ENDS

Investor Enquiries:

investors@medibio.com.au +61 8 6189 1155

Henry Jordan – Six Degrees Investor Relations <u>Henry.jordan@sdir.com.au</u> +61 431 271 538

About TrivarX Limited:

TrivarX (ASX: TRI) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). TrivarX is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au